By Brad Jennings
May 6, 2021 | 11:37 AM
Helping those with chronic arthritis pain is the goal of a Canadian life sciences company that is moving to human trials on a cannabis based medicine.
Brent Zettl, CEO of ZYUS, says over the past three years they’ve performed 30 pre-clinical trials to get to this point. Now, he says they have been approved by both the Australian and US health authorities, to proceed with phase one of the clinical trial. The first phase, being performed in Australia will look at the safety and efficacy of managing pain in those with osteoarthritis. Zettl says they will know later this fall the result of the first trial, and then early next year will move into a phase two clinical trial.
ZYUS Life Sciences Increases Global Patient Access to Medical Cannabinoids in Australia with Health House International Sales and Distribution Agreement
New agreement will enable patients in Australia to access ZYUS’ cannabinoid formulations as part of international expansion
SASKATOON, Saskatchewan (BUSINESS WIRE) ZYUS Life Sciences Inc. ( ZYUS ), a Canadian life sciences company leading scientific research and development in phyto-therapeutics, is pleased to announce that it has entered a new non-exclusive, multiyear agreement with Australian medical cannabis importer, HHI (Australia) Pty Ltd
(“Health House”), to sell and distribute ZYUS’ cannabinoid formulations to medical patients through wholesale agents, such as pharmacies and hospitals. The agreement covers cannabinoid formulations including oils, as well as future product categories when they become available, with supply expected to hit the Australian market as early as the second half of 2021.
By Ryan Young
A plant-based COVID-19 vaccine could become a reality next year.
The CEO of Saskatoon-based ZYUS Life Sciences, Brent Zettl, says through their partnership with VIDO-Intervac on the University of Saskatchewan campus, pre-clinical trials on animals will begin early next year.
The proteins in vaccines are usually animal-based, so this model would be unique.
Zettl says they have done tests of the antigen that is the basis of the vaccine against an antibody that is recognized as a threat, and it was successful.
Even though Pfizer already has a COVID-19 vaccine and other companies are closer to the finish line, Zettl says the research continues because it sets a baseline for future work, should another pandemic come around.
By News Room
(CJWW)
A plant-based COVID-19 vaccine could become a reality next year.
The CEO of Saskatoon-based ZYUS Life Sciences, Brent Zettl, says through their partnership with VIDO-Intervac on the University of Saskatchewan campus, pre-clinical trials on animals will begin early next year.
The proteins in vaccines are usually animal-based, so this model would be unique.
Zettl says they have done tests of the antigen that is the basis of the vaccine against an antibody that is recognized as a threat, and it was successful.
Even though Pfizer already has a COVID-19 vaccine and other companies are closer to the finish line, Zettl says the research continues because it sets a baseline for future work, should another pandemic come around.